Shenzhen YHLO Biotech Co., Ltd.

SHSE:688575 Stock Report

Market Cap: CN¥9.4b

Shenzhen YHLO Biotech Balance Sheet Health

Financial Health criteria checks 6/6

Shenzhen YHLO Biotech has a total shareholder equity of CN¥2.6B and total debt of CN¥842.0M, which brings its debt-to-equity ratio to 32.4%. Its total assets and total liabilities are CN¥4.1B and CN¥1.5B respectively. Shenzhen YHLO Biotech's EBIT is CN¥243.5M making its interest coverage ratio 88.1. It has cash and short-term investments of CN¥578.4M.

Key information

32.4%

Debt to equity ratio

CN¥841.98m

Debt

Interest coverage ratio88.1x
CashCN¥578.39m
EquityCN¥2.60b
Total liabilitiesCN¥1.49b
Total assetsCN¥4.09b

Recent financial health updates

Shenzhen YHLO Biotech (SHSE:688575) Has A Pretty Healthy Balance Sheet

Nov 27
Shenzhen YHLO Biotech (SHSE:688575) Has A Pretty Healthy Balance Sheet

Does Shenzhen YHLO Biotech (SHSE:688575) Have A Healthy Balance Sheet?

Jul 18
Does Shenzhen YHLO Biotech (SHSE:688575) Have A Healthy Balance Sheet?

Recent updates

Shenzhen YHLO Biotech (SHSE:688575) Has A Pretty Healthy Balance Sheet

Nov 27
Shenzhen YHLO Biotech (SHSE:688575) Has A Pretty Healthy Balance Sheet

We Think That There Are More Issues For Shenzhen YHLO Biotech (SHSE:688575) Than Just Sluggish Earnings

Nov 06
We Think That There Are More Issues For Shenzhen YHLO Biotech (SHSE:688575) Than Just Sluggish Earnings

Slammed 25% Shenzhen YHLO Biotech Co., Ltd. (SHSE:688575) Screens Well Here But There Might Be A Catch

Nov 04
Slammed 25% Shenzhen YHLO Biotech Co., Ltd. (SHSE:688575) Screens Well Here But There Might Be A Catch

Estimating The Intrinsic Value Of Shenzhen YHLO Biotech Co., Ltd. (SHSE:688575)

Oct 31
Estimating The Intrinsic Value Of Shenzhen YHLO Biotech Co., Ltd. (SHSE:688575)

Shenzhen YHLO Biotech (SHSE:688575) Is Reinvesting At Lower Rates Of Return

Oct 12
Shenzhen YHLO Biotech (SHSE:688575) Is Reinvesting At Lower Rates Of Return

Shenzhen YHLO Biotech Co., Ltd.'s (SHSE:688575) Price In Tune With Earnings

Aug 30
Shenzhen YHLO Biotech Co., Ltd.'s (SHSE:688575) Price In Tune With Earnings

Does Shenzhen YHLO Biotech (SHSE:688575) Have A Healthy Balance Sheet?

Jul 18
Does Shenzhen YHLO Biotech (SHSE:688575) Have A Healthy Balance Sheet?

Shenzhen YHLO Biotech Co., Ltd. (SHSE:688575) Not Lagging Market On Growth Or Pricing

May 23
Shenzhen YHLO Biotech Co., Ltd. (SHSE:688575) Not Lagging Market On Growth Or Pricing

Shenzhen YHLO Biotech's (SHSE:688575) Sluggish Earnings Might Be Just The Beginning Of Its Problems

May 01
Shenzhen YHLO Biotech's (SHSE:688575) Sluggish Earnings Might Be Just The Beginning Of Its Problems

There Are Reasons To Feel Uneasy About Shenzhen YHLO Biotech's (SHSE:688575) Returns On Capital

Mar 19
There Are Reasons To Feel Uneasy About Shenzhen YHLO Biotech's (SHSE:688575) Returns On Capital

Financial Position Analysis

Short Term Liabilities: 688575's short term assets (CN¥1.8B) exceed its short term liabilities (CN¥887.7M).

Long Term Liabilities: 688575's short term assets (CN¥1.8B) exceed its long term liabilities (CN¥600.0M).

Debt to Equity History and Analysis

Debt Level: 688575's net debt to equity ratio (10.1%) is considered satisfactory.

Reducing Debt: 688575's debt to equity ratio has reduced from 49.4% to 32.4% over the past 5 years.

Debt Coverage: 688575's debt is well covered by operating cash flow (87.2%).

Interest Coverage: 688575's interest payments on its debt are well covered by EBIT (88.1x coverage).

Balance Sheet

Discover healthy companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/21 07:08
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Shenzhen YHLO Biotech Co., Ltd. is covered by 9 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Pei ChengChina Galaxy Securities Co., Ltd.
Shiyu ChenChina International Capital Corporation Limited
Wei SunChina Merchants Securities Co. Ltd.